髓系成熟：ATRA 增强抗 PD-1？
Myeloid Maturity: ATRA to Enhance Anti-PD-1?
机构信息
University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
出版信息
Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652.
Abstract
Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.
摘要
髓系来源的抑制细胞（MDSC）与抗 PD-1 治疗的耐药性有关。全反式维甲酸（ATRA）可能诱导 MDSC 的成熟并改变其免疫抑制作用。将 ATRA 添加到 pembrolizumab 中可能靶向这种耐药机制，以增强基于抗 PD-1 的免疫治疗的总体影响。见 Tobin 等人的相关文章，第 1209 页。
相似文献
1
Myeloid Maturity: ATRA to Enhance Anti-PD-1?髓系成熟：ATRA 增强抗 PD-1？
Clin Cancer Res. 2023 Apr 3;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652.
2
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.用全反式维 A 酸靶向治疗伊匹单抗的黑色素瘤患者中的髓系来源抑制细胞。
Int Immunopharmacol. 2018 Oct;63:282-291. doi: 10.1016/j.intimp.2018.08.007. Epub 2018 Aug 16.
3
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.全反式维甲酸抑制髓源性抑制细胞功能增强抗 PD-L1 在宫颈癌中的疗效。
Sci Rep. 2022 Jun 10;12(1):9619. doi: 10.1038/s41598-022-13855-1.
4
Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy.全反式维甲酸阻断髓源性抑制细胞扩增可增强抗血管生成治疗的疗效。
Cancer Res. 2018 Jun 15;78(12):3220-3232. doi: 10.1158/0008-5472.CAN-17-3415. Epub 2018 Apr 19.
5
Novel Use of All-Trans-Retinoic Acid in A Model of Lipopolysaccharide-Immunosuppression to Decrease the Generation of Myeloid-Derived Suppressor Cells by Reducing the Proliferation of CD34+ Precursor Cells.全反式维甲酸在脂多糖免疫抑制模型中的新用途：通过减少CD34+前体细胞的增殖来减少髓源性抑制细胞的产生。
Shock. 2017 Jul;48(1):94-103. doi: 10.1097/SHK.0000000000000812.
6
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.用 ATRA 靶向 MDSC 分化：联合派姆单抗和全反式维甲酸治疗转移性黑色素瘤的 I/II 期临床试验。
Clin Cancer Res. 2023 Apr 3;29(7):1209-1219. doi: 10.1158/1078-0432.CCR-22-2495.
7
All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.全反式维甲酸通过靶向髓源性抑制细胞和抑制血管生成抑制肝癌进展。
Int Immunopharmacol. 2023 Aug;121:110413. doi: 10.1016/j.intimp.2023.110413. Epub 2023 Jun 8.
8
Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models.髓源性抑制细胞在鼠类癌症模型中的耗竭与成熟。
Methods Mol Biol. 2021;2236:67-75. doi: 10.1007/978-1-0716-1060-2_7.
9
All-trans-retinoic acid restores CD4+ T cell response after sepsis by inhibiting the expansion and activation of myeloid-derived suppressor cells.全反式维甲酸通过抑制髓系来源抑制细胞的扩增和激活来恢复脓毒症后 CD4+ T 细胞的反应。
Mol Immunol. 2021 Aug;136:8-15. doi: 10.1016/j.molimm.2021.04.025. Epub 2021 May 26.
10
Human Isogenic Cell Line Models for Neutrophils and Myeloid-Derived Suppressor Cells.用于中性粒细胞和髓源性抑制细胞的人源同基因细胞系模型。
Int J Mol Sci. 2020 Oct 18;21(20):7709. doi: 10.3390/ijms21207709.
引用本文的文献
1
Pulsatile sequential drug release system for cascade tumor deep penetration and differentiation therapy to enhance chemoimmunotherapy.用于级联肿瘤深度渗透和分化治疗以增强化学免疫治疗的脉冲式顺序药物释放系统
Sci Adv. 2025 Sep 5;11(36):eadr8001. doi: 10.1126/sciadv.adr8001. Epub 2025 Sep 3.
2
MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression.髓源性抑制细胞上的MARCO表达对其分化和免疫抑制至关重要。
Cell Death Discov. 2025 Jul 22;11(1):337. doi: 10.1038/s41420-025-02627-1.
3
Vitamin A and its influence on tumour extracellular matrix.维生素A及其对肿瘤细胞外基质的影响。
Discov Oncol. 2025 Jan 7;16(1):16. doi: 10.1007/s12672-025-01751-9.
4
Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.骨髓来源抑制细胞在结肠炎相关结直肠癌中的作用及潜在治疗策略。
J Cancer Res Clin Oncol. 2024 May 8;150(5):243. doi: 10.1007/s00432-024-05755-w.
5
[Research Progress of Granulocytic Myeloid-derived Suppressor Cells
in Non-small Cell Lung Cancer].[粒细胞髓源性抑制细胞在非小细胞肺癌中的研究进展]
Zhongguo Fei Ai Za Zhi. 2024 Jan 20;27(1):65-72. doi: 10.3779/j.issn.1009-3419.2023.106.28.
6
Cancer and Autoimmune Diseases as Two Sides of Chronic Inflammation and the Method of Therapy.癌症与自身免疫性疾病：慢性炎症的一体两面及其治疗方法
Curr Cancer Drug Targets. 2024;24(11):1089-1103. doi: 10.2174/0115680096282480240105071638.
7
Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking Back and Forward.卵巢癌中的髓源性抑制细胞（MDSCs）：回顾与展望。
Cells. 2023 Jul 22;12(14):1912. doi: 10.3390/cells12141912.
本文引用的文献
1
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.用 ATRA 靶向 MDSC 分化：联合派姆单抗和全反式维甲酸治疗转移性黑色素瘤的 I/II 期临床试验。
Clin Cancer Res. 2023 Apr 3;29(7):1209-1219. doi: 10.1158/1078-0432.CCR-22-2495.
2
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
3
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.髓源性抑制细胞作为癌症中免疫抑制调节因子及治疗靶点。
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. doi: 10.1038/s41392-021-00670-9.
4
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.立体定向体部放疗联合纳武利尤单抗和乌瑞利单抗或卡博利珠单抗治疗晚期实体瘤的 I 期研究。
Clin Cancer Res. 2021 Oct 15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. Epub 2021 Jun 24.
5
MDSC subtypes and CD39 expression on CD8 T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.骨髓来源抑制细胞亚群和 CD8 T 细胞上的 CD39 表达可预测晚期 NSCLC 患者抗 PD-1 免疫治疗的疗效。
Eur J Immunol. 2020 Nov;50(11):1810-1819. doi: 10.1002/eji.202048534. Epub 2020 Jul 9.
6
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤（KEYNOTE-006）：一项开放标签、多中心、随机、对照、III 期研究的 5 年随访后结果。
Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.
7
The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.作为免疫治疗药物开发范例的T细胞炎症性肿瘤微环境
Immunotherapy. 2019 Feb;11(3):155-159. doi: 10.2217/imt-2018-0171.
8
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.通过下游聚焦色氨酸-犬尿氨酸-芳烃轴重新构想癌症免疫治疗中的 IDO 途径抑制。
Clin Cancer Res. 2019 Mar 1;25(5):1462-1471. doi: 10.1158/1078-0432.CCR-18-2882. Epub 2018 Oct 30.
9
The success and the challenge of all-trans retinoic acid in the treatment of cancer.全反式维甲酸治疗癌症的成功与挑战。
Crit Rev Food Sci Nutr. 2019;59(sup1):S71-S80. doi: 10.1080/10408398.2018.1509201. Epub 2018 Oct 2.
10
Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.炎症细胞因子在感染性疾病中对髓系细胞生成的调节作用。
Cell Mol Life Sci. 2018 Apr;75(8):1363-1376. doi: 10.1007/s00018-017-2724-5. Epub 2017 Dec 7.
Zotero 插件